{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:03:28Z","timestamp":1786993408456,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":752,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jtct.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T01:35:07Z","timestamp":1612575307000},"page":"389.e1-389.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ruxolitinib Inhibits IFN\u03b3 Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells"],"prefix":"10.1016","volume":"27","author":[{"given":"Molly Mercedes","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel Joy","family":"Lipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Scandolara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bruker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavan","family":"Chinnadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.02.002_bib0001","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/leu.2013.205","article-title":"Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.02.002_bib0002","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2021.02.002_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2701","article-title":"Myeloproliferative and lymphoproliferative disorders: state of the art","volume":"38","author":"Rumi","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.2020005364","article-title":"Ruxolitinib for steroid-resistant acute GVHD","volume":"135","author":"Risitano","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.02.002_bib0006","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0009","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2005-07-2793","article-title":"Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell","volume":"107","author":"Stagg","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0010","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood-2009-02-207795","article-title":"Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties","volume":"114","author":"Francois","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0011","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell stem cell"},{"key":"10.1016\/j.jtct.2021.02.002_bib0012","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/stem.3035","article-title":"Potency analysis of mesenchymal stromal cells using a phospho-STAT matrix loop analytical approach","volume":"37","author":"Chinnadurai","year":"2019","journal-title":"Stem Cells"},{"key":"10.1016\/j.jtct.2021.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/stem.2580","article-title":"Proteasomal indoleamine 2,3-dioxygenase degradation reduces the immunosuppressive potential of clinical grade-mesenchymal stromal cells undergoing replicative senescence","volume":"35","author":"Loisel","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.jtct.2021.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.1301828","article-title":"IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells","volume":"192","author":"Chinnadurai","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0015","doi-asserted-by":"crossref","first-page":"e14698","DOI":"10.1371\/journal.pone.0014698","article-title":"Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO)","volume":"6","author":"Croitoru-Lamoury","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2021.02.002_bib0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.5HI0714-325R","article-title":"Involvement of the CX3CL1 (fractalkine)\/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease","volume":"97","author":"Brissot","year":"2015","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0017","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2005-05-1860","article-title":"CCR2 is required for CD8-induced graft-versus-host disease","volume":"106","author":"Terwey","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0018","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2016-08-736314","article-title":"Initiation of acute graft-versus-host disease by angiogenesis","volume":"129","author":"Riesner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2017-02-764696","article-title":"Vessels, T cells, and GVHD: time matters","volume":"129","author":"Haen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0020","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1172\/JCI0214793","article-title":"Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease","volume":"109","author":"Ordemann","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2021.02.002_bib0021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm1089","article-title":"Donor APCs are required for maximal GVHD but not for GVL","volume":"10","author":"Matte","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2021.02.002_bib0022","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jtct.2021.02.002_bib0023","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nm0602-575","article-title":"Acute graft-versus-host disease does not require alloantigen expression on host epithelium","volume":"8","author":"Teshima","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2021.02.002_bib0024","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.4049\/jimmunol.0803864","article-title":"Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype","volume":"182","author":"Romieu-Mourez","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/mt.2015.67","article-title":"Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase-mediated immune suppression, independent of autophagy","volume":"23","author":"Chinnadurai","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2021.02.002_bib0026","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e3181938998","article-title":"Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used","volume":"87","author":"Bartsch","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.02.002_bib0027","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.exphem.2005.02.004","article-title":"Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation","volume":"33","author":"Rieger","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0028","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1532\/IJH97.A10505","article-title":"Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin","volume":"82","author":"Wang","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0029","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.bbmt.2015.01.014","article-title":"Bone marrow mesenchymal stromal cells from patients with acute and chronic graft-versus-host disease deploy normal phenotype, differentiation plasticity, and immune-suppressive activity","volume":"21","author":"Copland","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.02.002_bib0030","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.02.002_bib0031","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2020007336","article-title":"Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness","volume":"136","author":"Mohty","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0032","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2021.02.002_bib0033","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/bloodadvances.2017006205","article-title":"Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNgamma priming","volume":"1","author":"Chinnadurai","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.02.002_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2012.00023","article-title":"The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics","volume":"3","author":"Castor","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/01.ATV.0000095360.62479.1F","article-title":"Fractalkine in vascular biology: from basic research to clinical disease","volume":"24","author":"Umehara","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0036","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1189\/jlb.5CE0814-385","article-title":"A new checkpoint in the path to GVHD? How bedside-to-bench stem cell transplant studies can inform human GVHD biology","volume":"97","author":"Barrett","year":"2015","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/j.jtct.2021.02.002_bib0037","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41232-016-0017-2","article-title":"Therapeutic intervention of inflammatory\/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway","volume":"36","author":"Imai","year":"2016","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.jtct.2021.02.002_bib0038","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1182\/blood-2009-06-227587","article-title":"Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality","volume":"114","author":"Jasperson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0039","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood-2007-06-096081","article-title":"Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality","volume":"111","author":"Jasperson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0040","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.02.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184254","article-title":"PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients","volume":"12","author":"Hossain","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2021.02.002_bib0042","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of Remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.02.002_bib0043","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.bbmt.2020.02.023","article-title":"Mesenchymal stromal cells for graft-versus-host disease: a trilogy","volume":"26","author":"Galipeau","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.02.002_bib0044","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/sctm.16-0485","article-title":"Safety profile of good manufacturing practice manufactured interferon gamma-primed mesenchymal stem\/stromal cells for clinical trials","volume":"6","author":"Guess","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jtct.2021.02.002_bib0045","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1182\/bloodadvances.2020002646","article-title":"Mesenchymal stromal cells in hematopoietic cell transplantation","volume":"4","author":"Burnham","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.02.002_bib0046","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2021.02.002_bib0047","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/stem.3028","article-title":"Molecular genetic and immune functional responses distinguish bone marrow mesenchymal stromal cells from hepatic stellate cells","volume":"37","author":"Chinnadurai","year":"2019","journal-title":"Stem Cells"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721006667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721006667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:38Z","timestamp":1763002838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721006667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2666636721006667"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.02.002","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib Inhibits IFN\u03b3 Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}